Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate.…
Both McDonald's and Pfizer are blue-chip laggards trading at a discount, both cut reliable dividend checks, and both promise retirees a place to park serious money. But one of them carries hidden…
Jim Cramer stared down a stock yielding over 6% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC's Mad…
Danielle Liverance The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker:…
Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines…
The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. That is exactly where…
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash,…
Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but…
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th…
Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat…
Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into…
I keep buying Pfizer (NYSE:PFE | PFE Price Prediction) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap…
Alex Sirois Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE | PFE Price Prediction). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and…
Alex Sirois At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a…
